Skip to main content
Access Resources

MJFF Publications

661 - 670 of 7370 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's disease
    Journal Name: Acta Ophthalmologica
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1111/j.1755-3768.2022.0786
    Best OA location URL:
    Citation Count: 0
  • OPEN
    Title: Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease
    Journal Name: Cell Stem Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.stem.2022.11.010
    Citation Count: 28
  • OPEN
    Title: Machine learning‐based prediction of cognitive outcomes in de novo Parkinson's disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.067067
    Citation Count: 0
  • RESTRICTED
    Title: Major advances in Parkinson's disease over the past two decades and future research directions
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3
    Best OA location URL:
    Citation Count: 2
  • OPEN
    Title: Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105925
    Citation Count: 6
  • OPEN
    Title: Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.08.002
    Citation Count: 3
  • RESTRICTED
    Title: Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
    Journal Name: Journal of Controlled Release
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jconrel.2022.10.050
    Best OA location URL:
    Citation Count: 17
  • OPEN
    Title: Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation
    Journal Name: Sleep Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.sleep.2022.09.025
    Citation Count: 5
  • OPEN
    Title: Orchestration of selective autophagy by cargo receptors
    Journal Name: Current Biology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.cub.2022.11.002
    Citation Count: 22
  • OPEN
    Title: P5B-ATPases in the mammalian polyamine transport system and their role in disease
    Journal Name: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa, publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.bbamcr.2022.119354
    Citation Count: 10
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.